MAGNITUDE®
Following the positive outcomes of the FORTITUDE® trial, R3 Vascular Medical continued its development to create a bioresorbable scaffold that provides the same strength, flexibility and, ultimately, diameter of bare metal stents, the current standard of care.
The MAGNITUDE® sirolimus-eluting bioresorbable scaffold (BRS) is the result of this development program. The sub-100 µm MAGNITUDE® is currently being evaluated in a clinical trial titled RENASCENT III, which is still being enrolled. R3 Vascular will provide additional clinical updates on the RENASCENT III trial as they become available.